NCT01006395View on ClinicalTrials.gov

Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Zoledronic acid

yearly infusion

DRUG

Placebo

yearly infusion

Trial Locations (1)

3084

Austin Health, Heidelberg

Sponsors

Lead Sponsor

Austin Health
All Listed Sponsors
lead

Austin Health

OTHER_GOV

NCT01006395 - Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) | Biotech Hunter | Biotech Hunter